A panelist discusses how the ARCHES and ARANOTE trials differ in their fundamental design elements, with ARCHES evaluating enzalutamide plus androgen deprivation therapy (ADT) vs placebo plus ADT in ...

Bipolar resection and enhanced imaging are preferred for NMIBC assessment, reflecting a trend towards advanced diagnostic tools. Pembrolizumab offers a distinct safety profile for BCG-unresponsive ...

Cleveland Clinic performed the first transcontinental robot-assisted HIFU focal therapy for prostate cancer, connecting Ohio and Abu Dhabi. The procedure involved remote operation by Dr. Ruben ...

Please share your concluding thoughts about the recent progress and future outlook of NMIBC.

If they are FDA approved, what impact are the novel delivery systems likely to have on patients’ quality of life? Treatment adherence?

Experts discuss their expectations regarding the uptake of new treatments in clinical practice for non–muscle-invasive bladder cancer and other relevant conditions.

Enzalutamide plus talazoparib significantly extended overall survival vs enzalutamide alone in mCRPC. Data from the phase 3 TALAPRO-2 trial (NCT03395197) showed that the combination of enzalutamide ...

“I think the great thing about Cost Plus Drugs is that, as we mentioned, it's simple, but it's also price transparent," says Raymond Xu, MD. “I think the great thing about Cost Plus Drugs is that, as ...

Ian Metzler, MD, discusses developments in imaging and treating stones. Technology for kidney stone surgery is rapidly evolving. In a recent interview with Urology Times®, Ian Metzler, MD, MTM, ...

SCONE therapy significantly improved neurogenic bladder symptoms, with over 50% of patients achieving a clinically significant response in the CONTINENCE trial. The therapy also showed additional ...

Emerging therapies, including sasanlimab, nadofaragene firadenovec, and Anktiva, are being explored for NMIBC, with a focus on combination treatments to enhance efficacy. Clinical trials like CREST, ...

"There really wasn't a difference in in surgical outcomes. The patients tolerated it very well,” says Joshua J. Meeks, MD, PhD. “From a urology perspective, I don't think we're going to see any ...